KA
GILD icon

Kovack Advisors’s Gilead Sciences GILD Stock Holding History

Kovack Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10
Closed -$2K – 474
2017
Q3 		$2K Buy
+10
New +$765 ﹤0.01% 350
2016
Q3 		– Sell
-6
Closed -$4K – 284
2016
Q2 		$4K Buy
+6
New +$532 ﹤0.01% 255
2015
Q4 		– Sell
-2
Closed -$1K – 245
2015
Q3 		$1K Buy
+2
New +$222 ﹤0.01% 217

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kovack Advisors's GILD Position: Q1 2026 in Review

Kovack Advisors reduced its Gilead Sciences (GILD) stake by 30% in Q1 2026, selling an estimated $1.07M and leaving 17,794 shares worth $2.48M. The position accounts for 0.13% of the portfolio, ranked #146.

Kovack Advisors first reported a position in GILD in Q3 2014 and has held it in 46 quarters since. The position peaked at $3.12M in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Kovack Advisors held 17,794 shares of Gilead Sciences worth $2.48M as of Q1 2026.
  • Kovack Advisors sold 7,627 Gilead Sciences shares in Q1 2026, an estimated $1.07M.
  • Gilead Sciences made up 0.13% of Kovack Advisors's portfolio in Q1 2026, its #146 holding.
  • Kovack Advisors first reported a position in Gilead Sciences in Q3 2014 and has held it in 46 quarters since.
  • Kovack Advisors's Gilead Sciences position peaked at $3.12M in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.